Company Overview of Intas Pharmaceuticals Ltd.
Intas Pharmaceuticals Limited engages in the development, manufacture, and marketing of pharmaceutical formulations worldwide. The company provides products in various therapeutic areas, such as neurology, psychiatry, cardiology diabetology, urology, nephrology, and pain management. It offers a portfolio of biosimilar products across microbial and mammalian cell culture products, such as Neukine, Erykine, Intalfa, Pegasta, Terifrac, Mabtas, and Folisurge, as well as plasma derived products, which are under various stages of development. The company also operates in animal health care industry and provides a range of products, including anti-parasites, skin care, anti-infectives, nutraceutica...
Off Nehru Bridge
Founded in 1985
Key Executives for Intas Pharmaceuticals Ltd.
Chief Executive Officer, Managing Director, Director, Member of Share Allotment Cum Transfer Committee, Member of Investor Grievance Committee, Member of IPO Committee and Member of CSR Committee
Chief Finance Officer, Member of Share Allotment cum Transfer Committee and Member of IPO Committee
Vice Chairman, Managing Director, Chairman of Compensation Committee, Member of Share Allotment Cum Transfer Committee, Member of Audit Committee, Member of Investor Grievance Committee, Member of IPO Committee and Member of CSR Committee
Managing Director, Executive Non Independent Director and Member of CSR Committee
Compensation as of Fiscal Year 2015.
Intas Pharmaceuticals Ltd. Key Developments
Intas Pharmaceuticals Not Seeking Listing
Sep 18 15
Intas Pharmaceuticals Ltd. is not seeking listing. "We don't feel the need to consider a listing for the next one to two years at least," chief financial officer Jayesh Shah said. "When we are thinking of it, we will explore all options, including an overseas listing."
Intas Pharmaceuticals Launches Biosimilar Version of Ranibizumab in India
Jun 24 15
Intas Pharmaceuticals announced that it has launched a "biosimilar" version of Roche's Lucentis (ranibizumab) in India. The biosimilar is marketed under the brand name Razumab and will reportedly be sold at a discount of some 25% against imported Lucentis. Lucentis is indicated for the treatment of wet age-related macular degeneration, macular oedema following retinal vein occlusion, and diabetic macular oedema. It remains unclear, however, for which of these indication Razumab is indicated. Significance:With details of the pathway used for the approval and the clinical data used to support its application remaining limited it is challenging to determine if Razumab is a biosimilar - i.e. in line with the definition of biosimilars in regulated markets. The company currently markets a growing portfolio of biosimilar products in India, including biosimilar erythropoietin, filgrastim, pegylated filgrastim, and rituximab. Launching in regulated markets does however require significant finances to conduct the clinical research needed to support market access and the marketing know-how to support market uptake once approved. Despite these challenges the company has launched a biosimilar version of Amgen's Neupogen (filgrastim) in Europe. It is important to note that the clinical data and marketing knowledge needed to launch a monoclonal antibody is substantially more significant than that needed to launch a less complex biologic such as filgrastim. In India, even with a 25% discount, the biosimilar may be out of reach for many in India's largely out-of-pocket market. This point, coupled with a preference for western brands among the wealthy, means that the market potential for Razumab in India may be limited.
Intas Launches Biosimilar Version of Amgen's Neupogen in Europe
Feb 24 15
Intas has launched a biosimilar version of Amgen's (US) neutropaenia drug Neupogen (filgrastim). The injectable drug is the first biosimilar manufactured by an Indian company to be approved in the tightly regulated EU market. According to a company statement, Phase III clinical trials (multi-centre safety and efficacy studies involving 120 female adult patients receiving chemotherapy to treat breast cancer) showed that Intas's filgrastim reduced severe neutropaenia to 1.4 days from an average of 1.6 and 1.8 days reported in other studies. Intas has confirmed that its lower-cost version of filgrastim, marketed under the brand name Accofil, has secured UK and Dutch tendering contracts, and expects to launch in Mexico and Brazil in the next six months. The company is looking to file for US approval in 2016, but would face competition at launch from Sandoz (subsidiary of Swiss firm Novartis), which has already filed for approval for Zarxio, another biosimilar version Neupogen. It is anticipated that the US FDA is likely to make a final decision regarding the approval of Zarxio in March.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|